The point-of-care, central laboratory and molecular diagnostics business said
As a result, reimbursement by
The cut in reimbursement level has no impact on management expectations for EKF as a whole, said the firm; Selah's DME panel is one of a number of molecular tests in the Selah portfolio. EKF said that the commercial rationale behind the acquisition is unaffected due to the considerable opportunity for Selah to continue to add market share.
"Whilst we would clearly have preferred reimbursement levels to have remained higher we are confident that Selah's overall portfolio will deliver an enhanced return to our shareholders. Selah's sales force has established relationships with over 300 physicians, a six-fold increase since
EKF announced that it had entered into a conditional agreement to buy US-based molecular diagnostics business
Most Popular Stories
- Want a Job? Try Minneapolis
- U.S. Stocks Start the Week on Shaky Ground
- 'Planet of the Apes' Still Rules the Box Office
- Small-Business Loans Fueling Economic Growth
- Tesco Head Steps Down After Profit Warning
- BlackBerry Appoints New COO from LiveOps Inc.
- GM Looking for Ignition Fix for Certain Cadillacs
- Judge OKs Warrant for Google User's Mails
- Startup Makes It Easier to Buy American
- Perry Deploying 1,000 Troops to Texas Border